Evidence map›Paper›PMID 38581432›Full record

ArticleThe Journal of infectious diseases2024

What Is the Economic Benefit of Annual COVID-19 Vaccination From the Adult Individual Perspective?

Sarah M Bartsch, Kelly J O'Shea, Colleen Weatherwax, Ulrich Strych, Kavya Velmurugan, Danielle C John, Maria Elena Bottazzi, Mustafa Hussein, Marie F Martinez, Kevin L Chin and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sarah M BartschPublic Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.
Kelly J O'SheaPublic Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.
Colleen WeatherwaxPublic Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.
Ulrich StrychNational School of Tropical Medicine, Department of Pediatrics, and Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, Houston, Texas, USA.
Kavya VelmuruganPublic Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.
Danielle C JohnPublic Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.
Maria Elena BottazziNational School of Tropical Medicine, Department of Pediatrics, and Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, Houston, Texas, USA.
Mustafa HusseinGraduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.
Marie F MartinezPublic Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.
Kevin L ChinPublic Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.
Allan CicirielloNational School of Tropical Medicine, Department of Pediatrics, and Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, Houston, Texas, USA.
Jessie HeneghanPublic Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.
Alexis DibbsPublic Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.
Sheryl A ScannellPublic Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.
Peter J HotezNational School of Tropical Medicine, Department of Pediatrics, and Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, Houston, Texas, USA.
Bruce Y LeePublic Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.

Funding

Project 4: Virtual Public Health Precision Nutrition LaboratoryU54TR004279 · NCATS · GRADUATE SCHOOL OF PUBLIC HEALTH AND HEALTH POLICY · PI Bruce Y Lee · 2022 to 2026
$5.4M
Simulating the Spread and Control of Multiple MDROs Across a Network of Different Nursing HomesP01AI172725 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI HUANG, SUSAN S. · 2023 to 2023
$2.9M
Regional Healthcare Ecosystem Analyst (RHEA) Modeling the Environment (MODE): SARS-CoV-2R01GM127512 · NIGMS · GRADUATE SCHOOL OF PUBLIC HEALTH AND HEALTH POLICY · PI LEE, BRUCE Y · 2020 to 2023
$2.1M
MOdeling Nursing homes to Affect Response to COVID-19 (MONARC)R01HS028165 · AHRQ · GRADUATE SCHOOL OF PUBLIC HEALTH AND HEALTH POLICY · PI LEE, BRUCE Y · 2021 to 2022
$993k
Agency for Healthcare Research and Quality 1R01HS028165-01AHRQ HHS R01 HS028165City University of New YorkNational Institute of Allergy and Infectious DiseasesNational Science Foundation 2054858NCATS NIH HHSNIAID NIH HHS P01 AI172725NIGMS NIH HHS R01 GM127512NIGMS NIH HHS R01GM127512NIH HHS U54TR004279
6 · The paper itself

Abstract

backgroundWith coronavirus disease 2019 (COVID-19) vaccination no longer mandated by many businesses/organizations, it is now up to individuals to decide whether to get any new boosters/updated vaccines going forward.

methodsWe developed a Markov model representing the potential clinical/economic outcomes from an individual perspective in the United States of getting versus not getting an annual COVID-19 vaccine.

resultsFor an 18-49 year old, getting vaccinated at its current price ($60) can save the individual on average $30-$603 if the individual is uninsured and $4-$437 if the individual has private insurance, as long as the starting vaccine efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is ≥50% and the weekly risk of getting infected is ≥0.2%, corresponding to an individual interacting with 9 other people in a day under Winter 2023-2024 Omicron SARS-CoV-2 variant conditions with an average infection prevalence of 10%. For a 50-64 year old, these cost-savings increase to $111-$1278 and $119-$1706 for someone without and with insurance, respectively. The risk threshold increases to ≥0.4% (interacting with 19 people/day), when the individual has 13.4% preexisting protection against infection (eg, vaccinated 9 months earlier).

conclusionsThere is both clinical and economic incentive for the individual to continue to get vaccinated against COVID-19 each year.

Indexed as

Cost-Benefit AnalysisCOVID-19COVID-19 VaccinesMarkov ChainsSARS-CoV-2VaccinationAdolescentAdultFemaleHumansMaleMiddle AgedUnited StatesYoung AdultCOVID-19 VaccinesboosterCOVID-19economicindividualmodelvaccination

Identifiers

PMID38581432
PMCPMC11326810

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.